Medullary thyroid carcinoma (MTC) · line 1 · Selpercatinib monotherapy (advanced/progressive RET-mutant MTC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-SELPERCATINIB-MTC-1L |
| ID | IND-MTC-ADVANCED-1L-SELPERCATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-MTC |
| Sources | SRC-NCCN-THYROID-2025 |
Notes
Standard 1L for the ~50-100% of advanced MTC that is RET-mutant (sporadic ~50% RET M918T; hereditary MEN2 ~100%). Reuses cross-disease DRUG-SELPERCATINIB.
Used By
Algorithms
ALGO-MTC-1L- ALGO-MTC-1L